Sheila Gujrathi Buys 130,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX - Get Free Report) Director Sheila Gujrathi bought 130,000 shares of the firm's stock in a transaction on Monday, December 23rd. The shares were bought at an average cost of $2.31 per share, with a total value of $300,300.00. Following the transaction, the director now directly owns 130,000 shares of the company's stock, valued at approximately $300,300. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Ventyx Biosciences Trading Up 2.6 %

NASDAQ VTYX traded up $0.06 on Thursday, hitting $2.33. 1,299,879 shares of the company's stock were exchanged, compared to its average volume of 2,038,414. The stock has a 50-day moving average of $2.29 and a 200-day moving average of $2.33. The stock has a market cap of $164.76 million, a price-to-earnings ratio of -0.99 and a beta of 0.48. Ventyx Biosciences, Inc. has a 52 week low of $1.67 and a 52 week high of $11.48.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in VTYX. Palumbo Wealth Management LLC bought a new position in shares of Ventyx Biosciences during the third quarter valued at $26,000. China Universal Asset Management Co. Ltd. grew its position in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company's stock valued at $30,000 after buying an additional 5,310 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Ventyx Biosciences in the second quarter valued at about $32,000. Intech Investment Management LLC acquired a new position in shares of Ventyx Biosciences in the third quarter worth approximately $42,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in Ventyx Biosciences by 41.1% in the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company's stock valued at $56,000 after acquiring an additional 7,096 shares during the last quarter. Institutional investors own 97.88% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on VTYX shares. Oppenheimer reissued an "outperform" rating and set a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a report on Friday, November 8th. HC Wainwright reiterated a "neutral" rating and issued a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $10.00.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.